Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and
efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with
platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate
rece...
Age: 18 years - 66+
Gender: All
A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK),
and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with
platinum-resistant ovarian cancer.
Age: 18 years - 66+
Gender: Female
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin
works in treating patients with stage II-IV low-grade serous carcinoma of the ovary,
fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of
...
Age: 18 years - 66+
Gender: Female
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with
atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or
primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such ...
Age: 18 years - 66+
Gender: Female